Neuroendocrine neoplasm

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…

This Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…

This study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This phase 3 trial tests whether a radioactive drug called 177Lu-Edotreotide (PRRT) works better than the daily pill everolimus for people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. About 324 participants are randomly assigned to …

This early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This phase II trial tests whether adding the drug triapine to standard radioactive therapy (lutetium Lu 177 dotatate) helps shrink or slow the growth of metastatic neuroendocrine tumors. About 94 adults with well-differentiated, somatostatin receptor-positive tumors will be rando…

This phase 2 trial is testing a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 17 people with advanced neuroendocrine cancer that has spread. The goal is to see if the combination can shrink tumors or stop them from growing. Cabozantinib blocks enzymes that…

This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum drug plus etoposide) helps people with advanced or metastatic extrapulmonary neuroendocrine carcinoma live longer. About 189 participants will be randomly assigned to receive ch…

This trial tests whether a radioactive drug called Lu-DOTA-TATE can shrink or slow neuroendocrine tumours — rare, slow-growing cancers that often spread before diagnosis. The drug delivers radiation directly to tumour cells that have a specific receptor on their surface. Research…

This study is testing a robotic device that doctors use through the anus to remove benign growths (polyps, adenomas) from the rectum and sigmoid colon. The goal is to see if the device can remove the entire growth in one piece safely, without causing bleeding or a hole in the bow…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. Researchers will also monitor side effects and how long any response l…

This phase II trial tests a new drug called PM8002, a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth and immune evasion. It is given together with standard chemotherapy (FOLFIRI) to people with advanced neuroendocrine tumors that have wors…

This early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tum…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV dose…

This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…

This phase 2 study tests a drug called 212Pb-DOTAMTATE, which delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have grown despite standard treatments. The goal is to see if the drug shrinks tumors and to check for side effects.

This early-phase study tests a new two-drug combination for people with advanced neuroendocrine tumors (NETs) that have stopped responding to standard treatments. The drugs are cabozantinib (a targeted therapy pill) and Lu-177 DOTATATE (a radioactive treatment that seeks out tumo…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…

This study tests whether adding telotristat ethyl to standard therapy can help control carcinoid syndrome and prevent heart damage in people with advanced neuroendocrine tumors. About 79 adults with metastatic disease who are already on stable somatostatin analog therapy will tak…

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…

This phase II trial is testing a combination of chemotherapy (carboplatin and etoposide) with immunotherapy (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib, in 20 people with advanced high-grade neuroendocrine tumors who have not had prior chemo…

This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…

This study tests a treatment called Lu-DOTATATE, which delivers radiation directly to neuroendocrine tumor cells. About 195 people with tumors that have gotten worse will receive up to 4 cycles of this therapy, with doses adjusted based on individual scans and blood tests. The ma…

This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …

This study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take …

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…

This Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could de…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study tests a new PET imaging technique that uses 10 to 100 times less radiation than standard scans. Researchers will inject 200 healthy volunteers and patients with a radioactive tracer and use a high-sensitivity scanner to see if image quality remains good enough for dete…

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …

This study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …

This study aims to create better guidelines for reading PET scans in people with neuroendocrine tumors. Researchers will compare new criteria against the current standard to see which better predicts if a tumor shrinks, grows, or stays the same. The study involves 11 participants…

This study looks at 500 people with advanced neuroendocrine tumors to see if starting with surufatinib or somatostatin analogs leads to better outcomes. Researchers will compare how long the cancer is controlled with each sequence. The goal is to provide real-world evidence to gu…

This pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is…

This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over…

This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…